| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Peter F Buckley, Jeffrey M Goldstein, Robin A Emsle. Efficacy and tolerability of quetiapine in poorly responsive, chronic schizophrenia. Schizophrenia research. vol 66. issue 2-3. 2004-05-04. PMID:15061246. |
with the notable exception of clozapine, there is at present insufficient information on the efficacy of atypical antipsychotic medications in patients with poorly responsive schizophrenia. |
2004-05-04 |
2023-08-12 |
Not clear |
| P Huezo-Diaz, M J Arranz, J Munro, S Osborne, A Makoff, R W Kerwin, J Austin, M O'Donova. An association study of the neurotensin receptor gene with schizophrenia and clozapine response. Schizophrenia research. vol 66. issue 2-3. 2004-05-04. PMID:15061255. |
an association study of the neurotensin receptor gene with schizophrenia and clozapine response. |
2004-05-04 |
2023-08-12 |
Not clear |
| Małgorzata Pietrasze. Significance of dysfunctional glutamatergic transmission for the development of psychotic symptoms. Polish journal of pharmacology. vol 55. issue 2. 2004-04-07. PMID:12926541. |
clozapine) also inhibit the effects of nmda antagonists; (3) postmortem and in vivo studies have revealed alterations in ionotropic glutamate receptors (nmda, ampa, ka) and their modulatory sites in schizophrenia; (4) compounds enhancing the function of nmda receptors potentiate the antipsychotic effects of neuroleptics in schizophrenic patients. |
2004-04-07 |
2023-08-12 |
Not clear |
| Shih-Jen Tsai, Chen-Jee Hong, Younger W-Y Yu, Ching-Hua Lin, Ling-Ling Li. No association of tumor necrosis factor alpha gene polymorphisms with schizophrenia or response to clozapine. Schizophrenia research. vol 65. issue 1. 2004-04-06. PMID:14623371. |
no association of tumor necrosis factor alpha gene polymorphisms with schizophrenia or response to clozapine. |
2004-04-06 |
2023-08-12 |
Not clear |
| Shih-Jen Tsai, Chen-Jee Hong, Younger W-Y Yu, Ching-Hua Lin, Ling-Ling Li. No association of tumor necrosis factor alpha gene polymorphisms with schizophrenia or response to clozapine. Schizophrenia research. vol 65. issue 1. 2004-04-06. PMID:14623371. |
tumor necrosis factor alpha (tnf-alpha), a potent immunomodulator and proinflammatory cytokine, has been implicated in schizophrenia pathogenesis and clozapine response. |
2004-04-06 |
2023-08-12 |
Not clear |
| Shih-Jen Tsai, Chen-Jee Hong, Younger W-Y Yu, Ching-Hua Lin, Ling-Ling Li. No association of tumor necrosis factor alpha gene polymorphisms with schizophrenia or response to clozapine. Schizophrenia research. vol 65. issue 1. 2004-04-06. PMID:14623371. |
the results of these investigations suggest that the tnf-alpha gene -308g/a variants do not play a major role in susceptibility to, clinical manifestations for, or clozapine response in, schizophrenia. |
2004-04-06 |
2023-08-12 |
Not clear |
| Alan S Bellack, Nina R Schooler, Stephen R Marder, John M Kane, Clayton H Brown, Ye Yan. Do clozapine and risperidone affect social competence and problem solving? The American journal of psychiatry. vol 161. issue 2. 2004-04-01. PMID:14754789. |
the purpose of this investigation was to evaluate the effects of clozapine and risperidone on social skill and problem solving in patients with schizophrenia. |
2004-04-01 |
2023-08-12 |
Not clear |
| Jefferson Becker, Irenio Gomes, Eduardo S Ghisolfi, Alice Schuch, Fernanda L Paula Ramos, João Arthur Ehlers, Daniel B Nora, Diogo R Lara, Jaderson C da Cost. Clozapine, but not typical antipsychotics, correct P50 suppression deficit in patients with schizophrenia. Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology. vol 115. issue 2. 2004-03-22. PMID:14744582. |
clozapine, but not typical antipsychotics, correct p50 suppression deficit in patients with schizophrenia. |
2004-03-22 |
2023-08-12 |
human |
| Robert R Conley, Deanna L Kelly, Charles M Richardson, Carol A Tamminga, William T Carpente. The efficacy of high-dose olanzapine versus clozapine in treatment-resistant schizophrenia: a double-blind crossover study. Journal of clinical psychopharmacology. vol 23. issue 6. 2004-03-19. PMID:14624201. |
the efficacy of high-dose olanzapine versus clozapine in treatment-resistant schizophrenia: a double-blind crossover study. |
2004-03-19 |
2023-08-12 |
Not clear |
| Laurel A Townsend, Rahul Manchand. Gains in speeded information processing following clozapine treatment of schizophrenia. Canadian journal of psychiatry. Revue canadienne de psychiatrie. vol 49. issue 1. 2004-03-09. PMID:14763687. |
gains in speeded information processing following clozapine treatment of schizophrenia. |
2004-03-09 |
2023-08-12 |
Not clear |
| Jan Volavka, Pal Czobor, Thomas B Cooper, Brian Sheitman, Jean-Pierre Lindenmayer, Leslie Citrome, Joseph P McEvoy, Jeffrey A Lieberma. Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol. The Journal of clinical psychiatry. vol 65. issue 1. 2004-03-02. PMID:14744169. |
prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol. |
2004-03-02 |
2023-08-12 |
Not clear |
| Uriel Heresco-Lev. Glutamatergic neurotransmission modulation and the mechanisms of antipsychotic atypicality. Progress in neuro-psychopharmacology & biological psychiatry. vol 27. issue 7. 2004-02-24. PMID:14642971. |
furthermore, the results of the first generation of clinical trials with glycine (gly) site agonists of the nmda receptor in schizophrenia suggest that this type of compounds (1) have efficacy and side effects profiles different than those of conventional neuroleptics and (2) differ in their synergic effects when used in addition to conventional neuroleptics versus clozapine and possibly additional atypical antipsychotics. |
2004-02-24 |
2023-08-12 |
Not clear |
| Tonmoy Sharma, Catherine Hughes, William Soni, Veena Kumar. Cognitive effects of olanzapine and clozapine treatment in chronic schizophrenia. Psychopharmacology. vol 169. issue 3-4. 2004-02-23. PMID:12845415. |
cognitive effects of olanzapine and clozapine treatment in chronic schizophrenia. |
2004-02-23 |
2023-08-12 |
Not clear |
| Uriel Heresco-Levy, Marina Ermilov, Pesah Lichtenberg, Gali Bar, Daniel C Javit. High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia. Biological psychiatry. vol 55. issue 2. 2004-02-23. PMID:14732596. |
clinical trials indicate that glycine site agonists of the n-methyl-d-aspartate (nmda) receptors may reduce negative and cognitive symptoms in treatment-resistant schizophrenia when used as adjuvants to conventional antipsychotics but possibly not to clozapine. |
2004-02-23 |
2023-08-12 |
Not clear |
| Istvan Bitter, Martin R K Dossenbach, Shlomo Brook, Peter D Feldman, Stephen Metcalfe, Carlo A Gagiano, János Füredi, György Bartko, Zoltan Janka, Csaba M Banki, Gabor Kovacs, Alan Breie. Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia. Progress in neuro-psychopharmacology & biological psychiatry. vol 28. issue 1. 2004-02-18. PMID:14687871. |
olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia. |
2004-02-18 |
2023-08-12 |
Not clear |
| Istvan Bitter, Martin R K Dossenbach, Shlomo Brook, Peter D Feldman, Stephen Metcalfe, Carlo A Gagiano, János Füredi, György Bartko, Zoltan Janka, Csaba M Banki, Gabor Kovacs, Alan Breie. Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia. Progress in neuro-psychopharmacology & biological psychiatry. vol 28. issue 1. 2004-02-18. PMID:14687871. |
clozapine has been the gold standard for treatment of patients with refractory schizophrenia but is associated with serious safety liabilities. |
2004-02-18 |
2023-08-12 |
Not clear |
| Istvan Bitter, Martin R K Dossenbach, Shlomo Brook, Peter D Feldman, Stephen Metcalfe, Carlo A Gagiano, János Füredi, György Bartko, Zoltan Janka, Csaba M Banki, Gabor Kovacs, Alan Breie. Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia. Progress in neuro-psychopharmacology & biological psychiatry. vol 28. issue 1. 2004-02-18. PMID:14687871. |
this 18-week, randomized, double-blind, parallel study compared treatment with either olanzapine (5-25 mg/day, n=75) or clozapine (100-500 mg/day, n=72) in patients with schizophrenia who were nonresponsive to, or intolerant of, standard acceptable antipsychotic therapy. |
2004-02-18 |
2023-08-12 |
Not clear |
| Adrienne C Lahti, Henry H Holcomb, Martin A Weiler, Deborah R Medoff, Kristin N Frey, Michael Hardin, Carol A Tamming. Clozapine but not haloperidol Re-establishes normal task-activated rCBF patterns in schizophrenia within the anterior cingulate cortex. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 29. issue 1. 2004-02-17. PMID:14520337. |
clozapine but not haloperidol re-establishes normal task-activated rcbf patterns in schizophrenia within the anterior cingulate cortex. |
2004-02-17 |
2023-08-12 |
human |
| Adrienne C Lahti, Henry H Holcomb, Martin A Weiler, Deborah R Medoff, Kristin N Frey, Michael Hardin, Carol A Tamming. Clozapine but not haloperidol Re-establishes normal task-activated rCBF patterns in schizophrenia within the anterior cingulate cortex. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 29. issue 1. 2004-02-17. PMID:14520337. |
using positron emission tomography (pet) with (15)o water, we compared task-induced rcbf patterns induced by haloperidol or clozapine in individuals with schizophrenia. |
2004-02-17 |
2023-08-12 |
human |
| Adrienne C Lahti, Henry H Holcomb, Martin A Weiler, Deborah R Medoff, Kristin N Frey, Michael Hardin, Carol A Tamming. Clozapine but not haloperidol Re-establishes normal task-activated rCBF patterns in schizophrenia within the anterior cingulate cortex. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 29. issue 1. 2004-02-17. PMID:14520337. |
the pattern seen in the haloperidol-treated sv group was similar to the unmedicated sv group in that acc activation was seen during the control task and no further activation was seen during the dec. we report that clozapine, but not haloperidol, normalizes anterior cingulate rcbf patterns in schizophrenia during a cognitive task. |
2004-02-17 |
2023-08-12 |
human |